| Patient | Hippocrates |
|---|---|
| Date of birth | 1937-01-10 |
| Identifiers | MRN HR-AC005-SYN; SSN (made up) 000-05-8153 |
| Document date | 2026-04-27 |
| Author | Eleni Vasquez-Okafor, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Eight-week review. [S]
Hippocrates has been to physical therapy every week and does his strength and balance exercises most days. The therapist visited his house three weeks ago; a second rail has been fitted on the stairs and night lights in the hall. He wears shoes with a back indoors. His knee pain on stairs is 3 of 10 with the gel most mornings, and he takes acetaminophen a few times a week. He had a cold two weeks ago that has cleared; he did not take the nighttime cold remedy again. He sleeps six to six and a half hours without a sleep aid. He has had no falls. He had a DXA scan this morning. [S]
| Element | Detail |
|---|---|
| Knee pain | 3 of 10 on stairs |
| DXA | Femoral neck T-score -1.7; total hip -1.4; spine -0.6 |
| FRAX | Major osteoporotic fracture 11 percent; hip 2.6 percent |
| Falls | None |
| Cold | Resolved |
| System | Result | Finding |
|---|---|---|
| Musculoskeletal | Positive | Knee ache on the hill; less on stairs |
| Respiratory | Negative | Cough gone |
| Integumentary | Negative | No rash where he applies the gel |
| Psychiatric | Negative | Mood good; sleeping without a sleep aid |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naproxen sodium 220 mg oral tablet, one or two tablets most days for knee pain, bought over the counter, for about two years; stopped at intake (Beers 2023: avoid chronic use) | One or two tablets by mouth up to twice a day, self-directed | Oral route | 2024-03-01 to 2026-03-02 | stopped | S |
| Diphenhydramine 25 mg oral capsule at bedtime three or four nights a week for sleep, bought over the counter; stopped at intake (Beers 2023: strongly anticholinergic) | One capsule at bedtime as needed, self-directed | Oral route | 2025-09-01 to 2026-03-02 | stopped | S |
| Acetaminophen 500 mg oral tablet, one or two tablets up to three times a day as needed for knee pain, no more than 3,000 mg in a day | One to two tablets by mouth every eight hours as needed; no more than six tablets a day | Oral route | 2026-03-02 | active | S |
| Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once daily | One tablet by mouth daily | Oral route | 2026-03-02 | active | S |
| Diclofenac 1% gel, 4 g rubbed into each painful knee up to four times a day | Apply 4 g to each painful knee up to four times a day | Topical route | 2026-03-16 | active | S |
| Sodium chloride 0.65% nasal spray, two sprays in each nostril as needed for congestion | Two sprays in each nostril up to every four hours as needed | Nasal route | 2026-04-13 to 2026-04-23 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-27 | Body height | 168 | cm | S |
| 2026-04-27 | Body weight | 64.4 | kg | S |
| 2026-04-27 | Body mass index (BMI) [Ratio] | 22.8 | kg/m2 | S |
| 2026-04-27 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2026-04-27 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 2026-04-27 | Heart rate | 66 | /min | S |
| 2026-04-27 | Respiratory rate | 16 | /min | S |
| 2026-04-27 | Body temperature | 36.4 | Cel | S |
| 2026-04-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-27 | DXA Femur [T-score] Bone density | -1.7 | {T-score} | -1.0 or higher is normal; between -1.0 and -2.5 is low bone mass; -2.5 or lower is osteoporosis | Low | S |
| 2026-04-27 | DXA Hip [T-score] Bone density | -1.4 | {T-score} | -1.0 or higher is normal; between -1.0 and -2.5 is low bone mass; -2.5 or lower is osteoporosis | Low | S |
| 2026-04-27 | DXA Lumbar spine [T-score] Bone density | -0.6 | {T-score} | May read falsely high with spinal osteoarthritis | Normal | S |
| 2026-04-27 | Major osteoporotic fracture 10-year probability [Likelihood] Fracture Risk Assessment | 11 | % | S | ||
| 2026-04-27 | Hip fracture 10-year probability [Likelihood] Fracture Risk Assessment | 2.6 | % | S | ||
| 2026-04-27 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 3 | {score} | S |
Vital signs recorded on 2026-04-27; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 134/72, pulse 66; weight 64.4 kg; height 168 cm, unchanged |
| Musculoskeletal | Both knees: crepitus, no effusion; quadriceps 4+ of 5 |
| Skin | No irritation over the knees |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Slower walking, knee pain on stairs and one near-fall in the past six months, found on the comprehensive geriatric assessment at intake: gait speed 0.78 m/s, Timed Up and Go 13.8 seconds, unable to hold a tandem stance for 10 seconds, grip 24 kg; cause under evaluation with a geriatric medicine consultation | resolved | confirmed | R26.81 | S — Synthetic presenting problem of normal aging found on a comprehensive geriatric assessment; superseded at the consultation, when knee osteoarthritis with reduced leg strength and balance was diagnosed. |
| Primary osteoarthritis of both knees, diagnosed clinically by the ACR criteria (knee pain, age over 50, morning stiffness under 30 minutes, crepitus, bony enlargement, no warmth), with reduced quadriceps strength and balance and an increased risk of falls; KOOS JR 62 | active | confirmed | M17.0 | S — Synthetic modern diagnosis made at the consultation: a common, mild condition of aging chosen for a figure with no documented illness; not a claim about his real knees. |
| Potentially inappropriate over-the-counter medicines (Beers 2023): naproxen most days for about two years and diphenhydramine for sleep three or four nights a week; both stopped at intake | resolved | confirmed | Z79.1 | S — Synthetic medication history found on the deprescribing review. |
| Low bone mass (femoral neck T-score -1.7, total hip -1.4) with vitamin D insufficiency (24 ng/mL); FRAX 10-year risk 11 percent major and 2.6 percent hip, below treatment thresholds | active | confirmed | M85.89 | S — Synthetic DXA finding at eight weeks; not a claim about his real bones. |
| Common cold (viral upper respiratory infection) with runny nose, sore throat and a mild cough, no fever, chest clear, oxygen saturation 97 percent; COVID-19 and influenza tests negative; resolved in about ten days | resolved | confirmed | J06.9 | S — Synthetic acute illness; not a historical claim. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Knee pain (0 to 10) | Every visit | Completed today | 3 of 10 on stairs |
| Survey | Knee function (KOOS JR) | Every visit | Deferred | KOOS JR was not given at this visit: the form was left out of the visit packet. No harm is likely: the pain score and examination were recorded today and both show improvement. Corrective action: KOOS JR added to the visit template for his osteoarthritis visits and booked for the four-month review |
| Examination | Knee examination (range of movement, effusion, alignment, crepitus) | Every visit | Completed today | Crepitus, no effusion; quadriceps 4+ of 5 |
| Self-management | Exercise and self-management (strength and balance program, tai chi) | Every visit | Completed today | Weekly physical therapy and exercises most days |
| Self-management | Home safety check | Once, after a fall or near-fall | Completed today | Done three weeks ago: second stair rail and night lights fitted |
| Examination | Gait speed, Timed Up and Go, 30-second chair stand and four-stage balance test | At intake and after a strength and balance program | Due | After the twelve-week program, at the four-month review |
| Medication safety | Medication review (Beers 2023): no NSAID tablets, sedating antihistamines or other anticholinergic medicines; over-the-counter purchases | Every visit | Completed today | No NSAID tablets or sleep aids; the nighttime cold remedy was not taken again |
| Medication safety | Topical diclofenac: skin and use | Every visit | Completed today | Most mornings; no skin irritation |
| Laboratory | ALT with regular acetaminophen near 3 g a day | With regular use near 3 g a day | Not indicated | A few doses a week |
| Imaging | DXA and FRAX | At assessment, then every two years if untreated | Completed today | Femoral neck -1.7, total hip -1.4, spine -0.6; FRAX 11 and 2.6 percent; no vertebral fracture |
| Examination | Standing height | Yearly | Completed today | 168 cm, unchanged |
| Laboratory | 25-hydroxyvitamin D | At baseline, after repletion, then yearly | Up to date | Recheck at four months |
| Self-management | Vaccination review | Yearly | Completed today | PCV20 today; RSV and recombinant zoster at the wellness visit |
| Survey | What matters most (4Ms) | Every visit | Completed today | Walking to his teaching again, stopping twice on the hill |
| Survey | Mentation: mood, memory and sleep (4Ms) | Every visit | Completed today | Mood good; sleeping without a sleep aid |
Goal progress:
Immunizations given today: Pneumococcal conjugate vaccine (PCV20), single dose, one or more years after PPSV23 at 65 [S]
Guideline basis: Age-Friendly Health Systems: the 4Ms (What Matters, Medication, Mentation, Mobility) (2026); American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023); Updating STEADI for Primary Care: Recommendations From the American Geriatrics Society Workgroup (2025); 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee (2019); The clinician's guide to prevention and treatment of osteoporosis (2022); Osteoporosis in men: an Endocrine Society clinical practice guideline (2012); CMID: Clinical Monitoring Intelligence Database, rheumatoid arthritis and osteoarthritis, and osteoporosis monographs (2026)
Follow-up: Annual wellness visit in six weeks. Four-month review with repeat gait, balance and strength measures, vitamin D and KOOS JR. Next scheduled visit 2026-06-08: subsequent annual wellness visit. [S]